Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Middle East respiratory syndrome coronavirus (MERS-CoV) is an emerging zoonotic coronavirus. First identified in 2012, MERS-CoV has caused over 2460 infections and a fatality rate of about 35% in humans. Similar to severe acute respiratory syndrome coronavirus (SARS-CoV), MERS-CoV likely originated from bats; however, different from SARS-CoV, which potentially utilized palm civets as its intermediate hosts, MERS-CoV likely transmits to humans through dromedary camels. Animal models, such as humanized mice and nonhuman primates, have been developed for studying MERS-CoV infection. Currently, there are no vaccines and therapeutics approved for the prevention and treatment of MERS-CoV infection, although a number of them have been developed preclinically or tested clinically. This book covers one editorial and 16 articles (including seven review articles and nine original research papers) written by researchers working in the field of MERS-CoV. It describes the following three main aspects: (1) MERS-CoV epidemiology, transmission, and pathogenesis; (2) current progress on MERS-CoV animal models, vaccines, and therapeutics; and (3) challenges and future prospects for MERS-CoV research. Overall, this book will help researchers in the MERS-CoV field to further advance their work on the virus. It also has important implications for other coronaviruses as well as viruses outside the coronavirus family with pandemic potentials.

cell–cell fusion --- hDPP4 --- n/a --- therapeutics --- animal models --- HCoV-229E --- Drivers --- camels --- rabbits --- SARS-CoV --- MERS-CoV --- MVA vaccine --- transmission --- RBD --- MERS-CoV nucleocapsid protein --- complement --- animal model --- pseudotyped virus --- combination --- MERS-coronavirus --- peptide --- mouse model --- spike protein --- receptor-binding domain --- prevention and treatment --- coronaviruses --- coronavirus spike glycoprotein --- therapeutic antibodies --- vaccine platforms --- mutation --- severe acute respiratory syndrome coronavirus --- pathogenesis --- fusion inhibitor --- Coronavirus --- murine CD8+ T cell epitope --- lipidomics --- authentic virus --- correlates of immunity --- vaccines --- neutralizing monoclonal antibodies --- Middle East respiratory syndrome coronavirus --- small-molecule inhibitor --- Middle East Respiratory Syndrome Virus --- DPP4 --- pyroptosis --- cross-neutralization --- inflammation --- Qatar --- spike proteins --- One Health --- HKU4 --- nanobodies --- mechanism of action --- neutralizing antibody --- host factors --- UHPLC–MS

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

SARS-CoV-2 has infected more than 105 million people worldwide. During this pandemic, researchers and clinicians have been working to understand the molecular mechanisms that underpin viral pathogenesis by studying viral–host interactions. Now, with the global rollout of various COVID-19 vaccines—based on the neutralization of the spike protein using different technologies—viral immunology and cell-based immunity are being investigated. Researchers are also studying how various SARS-CoV-2 genetic mutations will impact the efficacy of these COVID-19 vaccines. At the same time, various antiviral drugs have been identified or repurposed that have potential as anti-SARS-CoV-2 treatments. BRICS (Brazil, Russia, India, China, and South Africa) is the acronym used to associate five major emerging national economies. The BRICS countries are known for their significant influence on regional affairs, including being leaders in scientific and clinical research and innovation. This Special Issue includes researchers from BRICS countries, in particular South Africa, involved in the study of SARS-CoV-2 and COVID-19. Original articles, as well as new perspectives or reviews on the matter, were welcomed. Research in the fields of vaccine studies, pathogenesis, genetic mutations, viral immunology, and antiviral drugs were especially encouraged.

SARS-CoV-2 --- E484K --- variant of Interest --- genomic epidemiology --- Brazil --- immunoassay --- SARS-CoV-2 nucleocapsid protein --- epitope coverage --- quantitative antibody binding --- protein microarray --- SARS-CoV-2 antibodies --- humoral response --- COVID-19 --- nanotechnology --- detection --- treatment --- breakthrough --- VRDL --- Delta and Delta plus variant --- India --- vaccine --- dental aerosol-generating procedures --- extra-oral suction --- high-volume evacuation --- low-volume saliva ejector --- splatter --- aerosol --- convalescent plasma --- COVID-19 and nanotechnology --- nanomedicine in South Africa --- bioinformatics and vaccine development --- vaccine development in South Africa --- models --- different settings --- intervention strategies --- NSW --- coronavirus disease 2019 (COVID-19) --- severe acute respiratory syndrome coronavirus (SARS-CoV-2) --- neutralizing antibody (NAb) --- diabetes --- corticosteroids --- reverse zoonosis --- wildlife --- COVID-19 testing --- hospital mortality --- intubation

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

SARS-CoV-2 has infected more than 105 million people worldwide. During this pandemic, researchers and clinicians have been working to understand the molecular mechanisms that underpin viral pathogenesis by studying viral–host interactions. Now, with the global rollout of various COVID-19 vaccines—based on the neutralization of the spike protein using different technologies—viral immunology and cell-based immunity are being investigated. Researchers are also studying how various SARS-CoV-2 genetic mutations will impact the efficacy of these COVID-19 vaccines. At the same time, various antiviral drugs have been identified or repurposed that have potential as anti-SARS-CoV-2 treatments. BRICS (Brazil, Russia, India, China, and South Africa) is the acronym used to associate five major emerging national economies. The BRICS countries are known for their significant influence on regional affairs, including being leaders in scientific and clinical research and innovation. This Special Issue includes researchers from BRICS countries, in particular South Africa, involved in the study of SARS-CoV-2 and COVID-19. Original articles, as well as new perspectives or reviews on the matter, were welcomed. Research in the fields of vaccine studies, pathogenesis, genetic mutations, viral immunology, and antiviral drugs were especially encouraged.

Medicine --- Epidemiology & medical statistics --- SARS-CoV-2 --- E484K --- variant of Interest --- genomic epidemiology --- Brazil --- immunoassay --- SARS-CoV-2 nucleocapsid protein --- epitope coverage --- quantitative antibody binding --- protein microarray --- SARS-CoV-2 antibodies --- humoral response --- COVID-19 --- nanotechnology --- detection --- treatment --- breakthrough --- VRDL --- Delta and Delta plus variant --- India --- vaccine --- dental aerosol-generating procedures --- extra-oral suction --- high-volume evacuation --- low-volume saliva ejector --- splatter --- aerosol --- convalescent plasma --- COVID-19 and nanotechnology --- nanomedicine in South Africa --- bioinformatics and vaccine development --- vaccine development in South Africa --- models --- different settings --- intervention strategies --- NSW --- coronavirus disease 2019 (COVID-19) --- severe acute respiratory syndrome coronavirus (SARS-CoV-2) --- neutralizing antibody (NAb) --- diabetes --- corticosteroids --- reverse zoonosis --- wildlife --- COVID-19 testing --- hospital mortality --- intubation